Combined artemisinin derivatives; Plasmodium falciparum; Resistance; Uncomplicated malaria; Antimalarials; Drug Resistance; Europe; Humans; Malaria, Falciparum; Medicine (all)
Abstract :
[en] Malaria is a worldwide public health problem. In Europe, data show an increasing trend of imported cases in the last ten years. Following an alarming observation reporting resistance to anti-malarial drugs, new effective treatments have been developed in early 21st century. These are artemisinin and its derivatives. Artemisinin-based combination therapies (ACT) are now recommended by the World Health Organisation (WHO) since 2006 as the firstline treatment for uncomplicated Plasmodium falciparum malaria. However, resistance phenomena to these new drugs have been described in South-East Asia since 2009. It is thus necessary to use them properly and to monitor their use to preserve their effectiveness in the future.
Disciplines :
Immunology & infectious disease
Author, co-author :
PIRARD, Cyrielle ; Centre Hospitalier Universitaire de Liège - CHU > > Service des maladies infectieuses - médecine interne
Léonard, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > > Service des maladies infectieuses - médecine interne
Plum, Pierre-Emmanuel ; Université de Liège - ULiège > Département des sciences cliniques > GIGA-R : Immunopathologie - Maladies infectieuses et médecine interne générale
Struvay, S.; Service D'Infectiologie, CHU Liège, Belgium
Moutschen, Michel ; Centre Hospitalier Universitaire de Liège - CHU > > Service des maladies infectieuses - médecine interne
Language :
French
Title :
Les dérivés combinés de l'artémisinine : une avancée thérapeutique dans le contrôle du paludisme non compliqué à Plasmodium falciparum
Alternative titles :
[en] Therapeutic progress in the control of uncomplicated Plasmodium falciparum malaria
World Health Organization. (2019) World malaria report 2019. En ligne : https://www.who.int/malaria/publications/worldmalaria-report-2019/en/. Dernière consultation le 20 mars 2020.
Institute of tropical medicine Antwerp. (2018) Lecture notes on tropical medicine. En ligne : https://www.itg.be/E/illustratedlecture-notes. Dernière consultation le 20 mars 2020.
Bruneel F, Tubach F, Corne P, et al. Severe imported falciparum malaria : A cohort study in 400 critically ill adults. PLoS One 2010;5:e13236.
Institut Pasteur. https://www.pasteur.fr/fr. Dernière consultation le 20 mars 2020.
Eastman RT, Fidock DA. Artemisinin-based combination therapies: A vital tool in efforts to eliminate malaria. Nat Rev Microbiol 2009;7:864-74.
Lefèvre A, Léonard P. Artésunate et paludisme sévère en pédiatrie. Rev Med Liege 2019;74:503-7.
Stefan I. Combination therapy : A way to forestall artemisinin resistance and optimize uncomplicated malaria treatment. J Med Life 2015;8:326-8.
WHO. (2015) Policy brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria. En ligne : https://www.who.int/malaria/publications/atoz/policy-briefsingle-dose-primaquine-pf/en/. Dernière consultation le 20 mars 2020.
Mita T, Tanabe K, Kita K. Spread and evolution of Plasmodium falciparum drug resistance. Parasitol Int 2009;58:201-9.
Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361:455-67.
Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008;359:2619-20.
Thanh NV, Thuy-Nhien N, Tuyen NT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisininpiperaquine in the south of Vietnam. Malar J 2017;16:27.
Wang J, Krishna S, Xu C. A temporizing solution to "Artemisinin Resistance". N Engl J Med 2019;380:2087-9.
Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin piperaquine resistance in Plasmodium falciparum malaria in Cambodia : A multisite prospective cohort study. Lancet Infect Dis 2016;16:357-65.
Hamilton WL, Amato R, van der Pluijm RW, et al. Evolution and expansion of multidrug-resistant malaria in southeast Asia : A genomic epidemiology study. Lancet Infect Dis 2019;19:943-51.
